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Abstract: Methyl-CpG-binding protein 2 (MeCP2) is an X-linked epigenetic modulator whose dosage
is critical for neural development and function. Loss-of-function mutations in MECP2 cause Rett
Syndrome (RTT, OMIM #312750) while duplications in the Xq28 locus containing MECP2 and
Interleukin-1 receptor-associated kinase 1 (IRAK1) cause MECP2 duplication syndrome (MDS, OMIM
#300260). Both are rare neurodevelopmental disorders that share clinical symptoms, including
intellectual disability, loss of speech, hand stereotypies, vasomotor deficits and seizures. The main
objective of this exploratory study is to identify novel signaling pathways and potential quantitative
biomarkers that could aid early diagnosis and/or the monitoring of disease progression in clinical
trials. We analyzed by RT-PCR gene expression in whole blood and microRNA (miRNA) expression
in plasma, in a cohort of 20 females with Rett syndrome, 2 males with MECP2 duplication syndrome
and 28 healthy controls, and correlated RNA expression with disease and clinical parameters. We
have identified a set of potential biomarker panels for RTT diagnostic and disease stratification of
patients with microcephaly and vasomotor deficits. Our study sets the basis for larger studies leading
to the identification of specific miRNA signatures for early RTT detection, stratification, disease
progression and segregation from other neurodevelopmental disorders. Nevertheless, these data will
require verification and validation in further studies with larger sample size including a whole range
of ages.
Keywords: Rett syndrome; MECP2 duplication syndrome; MeCP2; miRNA biomarkers; micro-
cephaly
1. Introduction
Methyl-CpG-binding protein 2 (MeCP2) is a calcium-dependent DNA-binding protein
involved in chromatin organization [1,2], transcriptional regulation [3,4] and control of
protein translation via microRNA (miRNA)-mediated mechanisms [5]. MECP2 gene is
X-linked and its dosage is critical for neural development and function, as both defect and
excess of MeCP2 function have severe neurological consequences. Rett syndrome (RTT,
OMIM #312750) is mainly caused by loss-of-function mutations in MECP2, and MECP2
duplication syndrome (MDS, OMIM #300260) is associated with duplications in the Xq28
locus, with a minimal region of duplication containing MECP2 and the adjacent gene
Interleukin-1 receptor-associated kinase 1 (IRAK1) [6]. Both are rare neurodevelopmental
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disorders and altered MeCP2 function has been involved in other forms of autism and
intellectual disability [7].
RTT affects predominantly females, due to the early lethality in hemizygous males
and to the almost exclusive de novo mutations in the paternal germline [8]. Because
of X-chromosome inactivation (XCI), most RTT patients are somatic mosaics in MeCP2
deficiency, causing a broad spectrum of severity [9]. On the contrary, MDS mostly affects
males, and due to skewed XCI, most carrier females remain asymptomatic or develop a
wide range of behavioral and psychiatric symptoms [10]. Both MECP2-related disorders are
dynamic, progress over several stages and share some clinical characteristics and symptoms,
including severe intellectual disability, loss of speech, hand stereotypies, vasomotor deficits
and seizures [11].
RTT courses with apparently normal development during the first 6–18 months of
life, with subsequent arrest and a rapid regression of acquired skills; however, subtle
motor and behavioral defects, hypotonia and feeding problems often appear during early
infancy [12–16]. Epilepsy is a remarkable symptom and might appear at any moment
during lifetime, as well as neurobehavioral and autonomic breathing abnormalities [17–19].
During adolescence, most RTT girls develop scoliosis, early onset osteoporosis and lose
mobility, reaching a severely debilitated physical condition in adult age [20]. MDS courses
with infantile hypotonia and recurrent infections, and patients frequently develop epilepsy,
spasticity and scoliosis [21,22]. Diagnosis is based on clinical symptoms and due to the
mild and non-specific nature of the initial signs, definitive diagnosis is often delayed for
years [23,24]. Genetic variations in modifier genes are getting increased attention as they
may hold relevance to explain RTT and MDS disorders. In this sense, 69 new genes have
been recently identified as causative of RTT-related disorders [7].
As an epigenetic regulator, MeCP2 functions include control of energy and choles-
terol metabolism, neural development, synaptic excitatory/inhibitory balance, calcium
homeostasis, inflammatory response and immunity [7,25–28]. Recent preclinical data also
pointed to glycogen synthase kinase 3b (GSK3B) and nuclear factor kappa b subunit 1
(NFKB1) signaling, metabolism and inflammation as new promising targets in RTT [29,30].
Clinical trials have mainly focused on RTT patients [31], as the first MDS patients were
reported in 2005. To date, only a few trials revealed significant improvements, and one
of the reported drawbacks was that clinical severity scores were not optimal outcome
measures [32]. Thus, the identification of unbiased quantitative biomarkers that correlate
with clinical and/or quality of life data could add great value to the current measures,
not only for the follow-up of disease progression in clinical trials but also for aiding early
disease diagnosis.
Levels of RNA, including mRNA and miRNA in blood cells and biological fluids are
considered as potential biomarkers. Circulating miRNAs in biological fluids can be ideal
biomarker candidates, as they reflect the pathogenic state of the system and are highly
stable [33,34]. For example, miRNA dysfunction has been involved in neuropsychiatric
disorders like schizophrenia and autism spectrum disorders [35,36].
In the search for novel signaling pathways involved in MECP2-related syndromes and
potential quantitative biomarkers, we selected an exploratory cohort of 20 RTT females
with a known mutation in MECP2, 2 males with MDS and 28 healthy controls.
Based on preliminary studies in our labs, we identified a set of candidate genes and
related miRNAs that can modulate their protein translation and/or signaling pathways.
The selection criteria were genes and miRNAs that interact or are regulated by Brain-
Derived Neurotrophic Factor (BDNF) and/or MeCP2 (MECP2 E1/E2, IRAK1, DNMT1,
PTEN, LIN28A, miR-16-5p, miR-132-3p, miR-212-3p, miR-137-3p, miR-483-5p) or are dys-
regulated in RTT mice models or human studies (CACNA2D2, THBS1, THBS3, miR-138-5p,
miR-146a-5p, miR-125b-5p, Let-7a-5p, Let-7a-3p, miR-24-3p). We measured in whole
blood gene mRNA levels and in plasma, the levels of BDNF protein and circulating miR-
NAs [25,30,36–42]. The specificity and sensitivity of selected candidate biomarkers were
determined, and expression data correlated with clinical parameters.
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2. Materials and Methods
2.1. Patients and Controls
Patients were recruited for the study at Sant Joan de Déu Hospital in Barcelona. The
study comprised 20 female patients diagnosed with typical RTT with a known mutation in
MECP2, two male patients diagnosed with MDS and one asymptomatic MECP2 duplication
carrier female, all of them aged between 1 and 33 years. Clinical characteristics of the
patients are summarized in Table 1. The control group was composed of 28 healthy
females, ranging from 6 to 45 years with no history of learning difficulties or psychiatric
and behavioral problems, who underwent blood analysis in the context of minor surgical
interventions. Blood samples were collected after overnight fasting in anticoagulation
(EDTA) tube.
Clinical severity in RTT was assessed using a severity profile score described by
Monrós et al. [23] that includes age at onset of the first sign, microcephaly, sitting alone,
ambulation, language, respiratory function, epilepsy, hand use and the onset of stereotypies.
Higher scores indicate greater severity. Additional clinical symptoms were kyphoscoliosis,
growth failure, peripheral vasomotor deficits and bowel control.
Research Ethics Committee of Sant Joan de Déu Hospital approved the study and
informed consent was subscribed by patients and controls (when >18 years old) or by their
parents (when <18 years old) prior to the collection of data and samples. All methods were
performed in accordance with the relevant guidelines and regulations.
2.2. mRNA Expression Assays in Whole Blood
RNA from 500 µL of whole blood was extracted using miRCURY™ RNA Isolation
Kit—Cell & Plant (300110, Exiqon, Vedbaek, Denmark) following supplier instructions.
RNA concentration and purity were analyzed using IMPLEN NanoPhotometer® P-Class
(Implen, Munich, Germany). RNA samples (0.5–1 µg) were reverse transcribed to cDNA
(High Capacity cDNA Reverse Transcription Kit, 4368814, Applied Biosystems, Foster City,
CA) and Real-Time PCR was performed using TaqMan PCR Assays (4331182, Applied
Biosystems) with TaqMan Universal PCR Master Mix (4324018, Applied Biosystems) in
the 7900HT Real-Time PCR System (Applied Biosystems). GUSB and GAPDH were used
as endogenous controls. Table S1 summarizes the mRNA assays analyzed. Data analysis
was performed with Expression Suite Software (Life Technologies) and data expressed as
Relative Quantification (RQ) normalized with respect to GUSB.
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2.3. miRNA Expression Assays in Plasma
Whole blood was centrifuged at 2000 rpm for 10 min and the plasma obtained was
frozen at −80 ◦C until use. Free hemoglobin concentration was analyzed by spectrophoto-
metric analysis with IMPLEN NanoPhotometer® P-Class (Implen) before miRNA extrac-
tion. Absorbance was measured at 414 and 375 nm and the ratio between the absorbance
peaks, suggestive of the presence of free hemoglobin, was used for the quantitative deter-
mination of hemolysis [43]. Samples with a ratio greater than 2 were considered hemolyzed
and were discarded from further analysis. miRNA from 200 µL of plasma was extracted
using miRCURY™ RNA Isolation Kits–Biofluids (300112, Exiqon) following supplier in-
structions. Undiluted miRNA was specifically retrotranscribed to cDNA with TaqMan®
MicroRNA Reverse Transcription Kit (4366596, Applied Biosystems) and miRNA primers
(4427975, Applied Biosystems). Real-Time PCR was performed as previously explained.
Table S1 summarizes the miRNA assays analyzed. There is no universally accepted nor-
malization for miRNAs in plasma. Thus, to avoid this problem we used a ratio-based
normalization previously described in Deng et al. [44]. Briefly, the differences in the CTs of
two miRNAs are the log (base 2) ratio value of these miRNAs.
∆CT = log2 (miRNA1/miRNA2) = log2
(








∆CT = CT miRNA2 −CT miRNA1 (3)
The calculation of the difference between the two groups was with the following
equations:
Ratiox vs y = mean ∆CTx (miRNA1/miRNA2) − mean ∆CTy (miRNA1/miRNA2) (4)
Fold change = 2Ratio (5)
Based on the equation of miRNA ratios, a fold change >1 implies an upregulation of
miRNA ratio in group x with respect to group y. Conversely, a fold change <1 implies a
downregulation of the miRNA ratio in group x with respect to group y.
2.4. Methodologic Considerations
Sample exclusion criteria were threshold cycles (Cts) higher than 35, replicates with a
standard deviation greater than 0.25 and Cts of endogenous controls not consistent. mRNA
data were calibrated to three control samples that were considered technically perfect.
2.5. Brain-Derived Neurotrophic Factor (BDNF) Protein Detection
BDNF was measured in duplicates in plasma samples using RayBio® Human BDNF
ELISA Kit following supplier instructions.
2.6. Fibroblasts Primary Cultures
We are indebted to the “Biobanc de l’Hospital Infantil Sant Joan de Déu per a la
Investigació” integrated in the Spanish Biobank Network of ISCIII for the sample and the
data procurement.
Cellular miRNAs from fibroblasts cultures were extracted using miRNeasy Mini Kit
(217004, Qiagen, Düsseldorf, Germany) following supplier instructions. Retrotranscription
and Real-Time PCR were performed as previously explained, and data expressed as relative
quantification were normalized with respect to the small-nucleolar RNA RNU48.
2.7. Statistical Analysis
Data were analyzed with SPSS program (IBM SPSS Statistics 24.0). We used non-
parametric Mann–Whitney U test to establish differences between conditions and Kruskal–
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Wallis test to correlate with clinical variables, as most of the samples did not follow the
normal distribution (Shapiro–Wilk normality test) and the sample size was insufficient
to presume normality within the data. To find a correlation between numeric variables
we used a bivariate correlation test. When performing multiple comparisons, significant
values were adjusted by Bonferroni correction. Statistical significance was set at p-values
* p < 0.05, ** p < 0.01 and *** p < 0.001.
The accuracy of candidate biomarkers to discriminate between patients and controls
or between symptoms was evaluated by plotting receiver operating characteristic (ROC)
curves and measuring the area under a ROC curve (AUC) and by using the Youden index
(J = Sensitivity + Specificity—1). AUC values of 0.9–1 are considered excellent, 0.8–0.9
good, 0.7–0.8 fair and <0.7 worthless. J = 0 indicates the same proportion of positive results
for groups with and without the disease. J = 1 indicates that there are no false positives or
false negatives. Combination of biomarkers was evaluated by logistic regression.
3. Results
3.1. Patients
Only RTT patients diagnosed as typical RTT with known mutations in the MECP2
gene entered the study, ranging from 5 to 33 years old at the time of blood extraction. Out
of the 20 patients, 10 had missense mutations and 10 had deletions and nonsense mutations
resulting in a truncated protein. Two young male MDS patients, to serve as reference of
increased MeCP2 function, and one asymptomatic female carrier of MECP2 duplication
were also included in the study. XCI was determined for RTT patients. Clinical severity
scores are included in Table 1. In our cohort, there was no correlation between severity
score and XCI (ρ = −0.408, p = 0.132), data consistent with previous publications [45].
3.2. Expression of mRNA in Blood and BDNF Protein in Plasma
In this study, we only used samples that passed the exclusion criteria standards
described in the methods section. We analyzed mRNA expression in total blood of 21 female
controls (6 to 45 years) and 16 female RTT (5 to 33 years). We also included 2 male MDS
patients (1, 4 years), and 1 adult MECP2 duplication carrier asymptomatic female. Table 2
summarizes average expression of BDNF and potential mRNA biomarkers.
Table 2. Expression of mRNA in peripheral blood and BDNF protein in plasma.
Controls (n = 21) RTT (n= 16) MDS (n = 2) MDC (n = 1)
mRNA (RQ)
CACNA2D2 1.07 ± 0.36 [0.88–1.25] 1.20 ± 0.62 [0.84–1.56] 0.85 ± 0.55 1.37
DNMT1 1.03 ± 0.24 [0.91–1.15] 1.11 ± 0.32 [0.94–1.28] 1.17 ± 0.20 1.12
IRAK1 1.02 ± 0.21 [0.92–1.13] 1.04 ± 0.24 [0.87–1.22] 2.52 ± 0.25 * 0.97
LIN28A 1.28 ± 0.84 [0.89–1.68] 0.73 ± 0.70 [0.34–1.12] * 0.75 ± 0.02 1.33
MECP2 E1 1.04 ± 0.29 [0.89–1.20] 1.78 ± 0.91 [1.02–2.54] * 1.85 ± 0.38 * 0.94
MECP2 E2 1.03 ± 0.26 [0.90–1.17] 1.58 ± 0.87 [0.96–2.21] ** 1.71 ± 0.51 * 1.01
PTEN 1.04 ± 0.31 [0.87–1.22] 0.91 ± 0.50 [0.55–1.27] 0.84 ± 0.14 0.92
THBS1 1.22 ± 0.88 [0.76–1.67] 1.67 ± 1.54 [0.81–2.52] 1.22 ± 0.81 1.39
THBS3 1.02 ± 0.21 [0.91–1.13] 1.46 ± 0.43 [1.21–1.71] *** 0.87 ± 0.08 -
Protein (ng/mL)
BDNF 128.68 ± 87.25[87.85–169-51]
80.55 ± 50.55
[52.11–188.55] - -
Results shown as mean ± standard deviation, [inferior-superior] 95% confidence interval. Statistically significant differences highlighted in
bold. * p < 0.05, ** p < 0.01, *** p < 0.001 indicate significant differences with respect to the control group (Mann–Whitney U Test). RQ:
relative quantification; MDC: MECP2 duplication carrier.
As expected, MECP2 E1 and E2 isoforms and IRAK1 mRNA levels in blood were
significantly higher in MDS patients than in control individuals (p = 0.026, p = 0.023 and
p = 0.012, respectively), as both genes are duplicated in MDS. In these patients, we found no
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other changes in the mRNAs analyzed. Less expected was that mRNA levels of MECP2 E1
and E2 isoforms were also elevated in RTT samples (p = 0.023 and p = 0.007, respectively).
MECP2 expression did not correlate with the type of mutation, which might indicate a
compensatory increase in transcription rate in response to reduced or dysfunctional MeCP2
protein. Thus, despite similar MECP2 mRNA increment in RTT and MDS, it results in a
reduction in the functional MeCP2 protein in RTT and an increase in functional protein
in MDS.
In RTT samples, mRNA expression of THBS3 was significantly higher (p = 0.001), while
LIN28A was significantly lower (p = 0.014) than in the control group (Table 2, Figure 1A).
The expression of THBS1, CACNA2D2, DNMT1 and PTEN mRNA showed no significant
differences between groups. BDNF protein levels in plasma were highly variable with no
significant differences between groups.
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Figure 1. Potential mRNA biomarkers for Rett Syndrome (RTT) detection. (A) Graphs showing
changes in mRNA expressi n of LIN28A and THBS3 between controls and RTT patients. (B) Changes
in IRAK1 expression between controls and RTT patients in t o age groups (<15 years, >15 years).
(C) Heat map of Spearman correlation between gene expressions in whole blood; 1 is positive
correlation, 0 no correlation and −1 is negative correlation. Statistically significant correlations
(p < 0.05) are black boxed. (D) Receiver operating characteristic (ROC) curves for the candidate genes
and their combinations assessing biomarker performance for RTT. (E) Graph showing changes in
Brain-Derived Neurotrophic Factor (BDNF) protein dosage regarding methyl-CpG-binding protein 2
(MECP2) mutation type and ROC curve assessing biomarker performance. * p < 0.05, *** p < 0.001
significant differences Mann–Whitney U test.
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As clinical manifestations in RTT and MDS evolved with time, we calculated Spearman
coefficient to assess age-related changes in potential mRNA biomarkers or BDNF protein
(Table S2). The few MDS samples included in this study also precluded this type of analysis.
We found a positive correlation with age for MECP2 E2 in control samples but not within
RTT samples. We did not find significant correlations with age in the other genes analyzed.
To unravel nonlinear age-dependent changes, we divided RTT and control samples into
two groups, <15 and >15 years old, and compared gene expression within each age group.
Again, we found no significant age-dependence. However, IRAK1 mRNA expression in
RTT patients <15 years old was lower at the limit of significance (p = 0.051) than in the
corresponding controls, while in RTT patients >15 years old it was higher (p = 0.028) than in
the corresponding controls (Figure 1B), suggesting nonlinear changes in IRAK1 expression
with age. Except for IRAK1, we discarded age as a variable in the subsequent analysis.
To identify relationships between the expression levels of mRNAs and BDNF, we
performed a correlation analysis by determination of the Spearman coefficient of pairwise
comparisons for each candidate biomarker (Figure 1C). Spearman coefficient (ρ) of 1 or −1
represents perfect positive or negative correlation, respectively.
As predictable, there was a significant positive correlation between the expression
of MECP2 E1 and MECP2 E2. Both isoforms also correlated positively with its well-
known interactor DNMT1, and negatively with LIN28A. MECP2 E2 isoform also correlated
positively with THBS1 and negatively with PTEN, highlighting the specific functions
previously described for each MECP2 isoform [46]. CACNA2D2 expression positively
correlated with DNMT1 and with THBS1, while THBS1 and THBS3 positively correlated
between them. Finally, BDNF levels did not correlate with the mRNAs analyzed.
3.3. Evaluation of mRNA in Blood and BDNF Protein in Plasma as Potential Molecular
Biomarkers for RTT
To evaluate the potential biomarker effectiveness, we applied ROC analysis and
calculated the AUC and J, under nonparametric assumption, for each candidate. We
also calculated the AUC and J for each possible biomarker combination that individually
reached statistical significance (Table 3). As RTT patients are mosaic for mutated and wild
type MECP2, we removed MECP2 E1 and E2 isoforms from this analysis. The few MDS
patients included in this study precluded this type of analysis.
Table 3. BDNF and mRNA performance as RTT biomarkers.
AUC DE p Value 95% CI J Trend n
RTT vs. Controls
THBS3 0.840 0.083 0.001 0.678–1 0.727 ↑ 14 vs. 17
LIN28A 0.747 0.087 0.014 0.576–0.917 0.467 ↓ 15 vs. 20
LIN28A + THBS3 0.899 0.057 0.0003 0.787–1 0.687 13 vs. 16
MECP2 mutation
type (MS vs. NS)
BDNF 0.811 0.099 0.022 0.617–1 0.500 ↓ 10 vs. 9
AUC: area under the curve; DE: deviation error; CI: confidence interval; J: Youden index; NS: nonsense;
MS: missense.
For discerning RTT patients from controls, biomarker performance was good for
THBS3 mRNA (AUC = 0.840) and fair for LIN28A mRNA (AUC= 0.747), slightly changing
when combined (Figure 1D), suggesting that altered THBS3 and LIN28A signaling might
be a hallmark of RTT patients.
Patients had clinical evaluation, but healthy control subjects did not. Therefore, to
identify potential biomarkers for individual clinical symptoms we compared RTT patients
with or without a particular symptom and calculated their AUC and J coefficients. No
mRNA biomarkers correlated with the onset of first symptom, sitting ability, ambulation,
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epilepsy, microcephaly, growth failure, kyphoscoliosis, onset of stereotypies and hand use,
bowel control, language, vasomotor deficits or severity score (Tables S3 and S4).
Within RTT patients, BDNF protein content in plasma was lower in nonsense-type
mutations that produce a truncated protein, with a good biomarker accuracy (AUC = 0.811).
However, due to the low BDNF protein reduction, the significance between groups disap-
peared when compared with controls (Figure 1E).
3.4. Identification of a Potential miRNA Biomarker Signature for RTT in Plasma
For miRNA detection, we used a fixed volume of plasma (200 µL) and only included
samples without hemolysis, as explained in the methods section. Therefore, miRNA was
determined in plasma samples of 11 controls, 14 RTT, 1 MDS and 1 MECP2 duplication
carrier. Out of the 11 miRNAs analyzed, four did not amplify enough to pass the control
standards (miR-137-3p, Let-7a-3p, miR-212-3p and miR-138-5p). From the remaining seven
miRNAs (mirR-16-5p, miR-132-3p, miR-146a-5p, miR-125b-5p, miR-483-5p, Let-7a-5p, miR-
24-3p), all but miR-483-5p and miR-132-3p were more expressed in RTT than in control
samples (Table S5).
We then performed Spearman correlation between levels of candidate miRNA. Nearly
all positively correlated with each other, except miR-125-5p and miR-483-5p (Figure 2A).
Next, we applied the ratio-based normalization previously described [44]. The only MDS
sample that passed hemolysis control precluded further analysis.
When correlating miRNA ratios with age (Table S2) we found that only miR-483-
5p/miR-16-5p significantly increased with age in RTT patients (ρ = 0.602, p = 0.05). On the
contrary, the same ratio in controls showed a negative correlation with age at the limit of
significance (ρ= −0.635, p = 0.091), data consistent with previous descriptions of decreasing
miR-483-5p expression with age [38]. Thus, we plotted miR-483-5p/miR-16-5p pair against
age for RTT patients and controls (Figure 2B). In infant age, miR-483-5p/miR-16-5p ratio
was high in controls, decreasing in adulthood, while it was very low in infant RTT patients,
slowly increasing with age to reach the controls’ adult range. The regression lines have
significant differences in slope (p = 0.0048) and y-intercept (p = 0.007) indicating an early
reduction in miR-483-5p/miR-16-5p ratio in RTT infants, which is corrected with time. The
only MDS patient (4 years old) had the miR-483-5p/miR-16-5p ratio in the range of its
age-matched control (5 years old), pointing to the specificity of this reduction in RTT.
Considering samples of all ages together, the ratio miR-24-3p/miR-132-3p was signif-
icantly higher in RTT group with respect to controls; miR-146a-5p/miR-132-3p and Let-
7a-5p/miR-132-3p were also higher in RTT at the limit of statistical significance (Table 4).
miR-24-3p/miR-132-3p ratio had good biomarker performance for RTT (AUC = 0.844),
increasing up to very good (AUC = 0.9) when combined with miR-146a-5p/miR-132-3p
ratio (Figure 2C).
Next, we analyzed miRNA ratios in the group of age >15 years old, as only one control
sample <15 years old passed the hemolysis test. Again, miR-24-3p/miR-132-3p, miR-146a-
5p/miR-132-3p and Let-7a-5p/miR-132-3p ratios were significantly higher in RTT with
respect to the control group (p = 0.005, p = 0.008 and p = 0.02, respectively) with very good
biomarker performance (AUC = 0.917, 0.875 and 0.938, respectively). No combination of
ratios improved biomarker performance (Table 4, Figure 2D). The rest of the ratios showed
no relevant changes.
These results suggest mild age-dependent changes in miRNA expression and that
miR-24-3p, miR-146a-5p and let-7a-5p relative to miR-132-3p might be potential candidates
to include in a quantitative biomarker panel for RTT identification in plasma samples.
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Table 4. Plasma miRNA ratios and performance as RTT biomarkers.
Ratio FC p-Value AUC p-Value 95% CI J Trend n
RTT vs. Controls
miR-24-3p/miR-132-3p 1.143 2.209 0.01 0.844 0.011 0.64–1 0.778 ↑ 10 vs. 9
miR-146a-5p/miR-132-3p 1.046 2.065 0.056 0.758 0.053 0.505–1 0.667 ↑ 11 vs. 9
Let-7a-5p/miR-132-3p 0.74 1.670 0.067 0.747 0.063 0.495–1 0.687 ↑ 11 vs. 9
miR-24-3p/miR-132-3p +
miR-146a-5p/miR-132-3p 0.9 0.003 0.954–1 1 10 vs. 9
RTT vs. Controls >15 years
Let-7a-5p/miR-132-3p 1.471 2.772 0.02 0.938 0.007 0.804–1 0.875 ↑ 6 vs. 8
miR-24-3p/miR-132-3p 1.453 2.737 0.005 0.917 0.01 0.751–1 0.875 ↑ 6 vs. 8
miR-146a-5p/miR-132-3p 1.685 3.214 0.008 0.875 0.02 0.671–1 0.75 ↑ 6 vs. 8
FC: Fold Change; AUC: area under the curve; CI: confidence interval; J: Youden index.
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3.5. Identification of a Potential Biomarker Signature for Clinical Parameters in RTT
As described above, to identify potential biomarkers for individual clinical symptoms we
compared RTT patients with or without a particular symptom and calculated their AUC and J
coefficients (Tables S3 and S4). We did not find correlation between potential biomarkers and
severity score, and out of all clinical parameters analyzed (shown in Table 1), we only identi-
fied clinical relevant and statistically significant potential biomarkers for microcephaly and
vasomotor disorders (Table 5).
Table 5. Plasma miRNA ratios and performance as RTT stratification biomarkers.
Ratio FC p-Value AUC p-Value 95% CI J Trend n
Microcephaly (Yes vs. No)
Let-7a-5p/miR-125b-5p 2.693 6.466 0.025 0.963 0.021 0.857–1 0.889 ↑ 9 vs. 3
Let-7a-5p/miR-16-5p 2.397 5.266 0.022 0.924 0.029 0.779–1 0.818 ↑ 11 vs. 3
miR-146a-5p/miR-132-3p 1.22 2.33 0.003 0.917 0.041 0.731–1 0.750 ↑ 8 vs. 3
Any combination of two miRNA ratios 1 0.013–0.02 1–1 1
Vasomotor deficits (Yes vs. No)
miR-146a-5p/miR-132-3p 1.438 2.709 0.002 0.964 0.014 0.859–1 0.857 ↑ 7 vs. 4
Let-7a-5p/ miR-16-5p 2.501 5.659 0.004 0.944 0.008 0.827–1 0.778 ↑ 9 vs. 5
miR-132-3p /miR-16-5p 1.187 2.278 0.017 0.933 0.018 0.78–1 0.833 ↑ 6 vs. 5
miR-24-3p /miR-16-5p 2.244 4.736 0.019 0.889 0.020 0.713–1 0.689 ↑ 9 vs. 5
Let-7a-5p/miR-125b-5p 2.232 4.696 0.04 0.857 0.042 0.638–1 0.714 ↑ 7 vs. 5





1 0.004–0.008 1–1 1
FC: Fold Change; AUC: area under the curve; CI: confidence interval; J: Youden index.
Acquired microcephaly within RTT patients was detected with very good accuracy
by three miRNA ratios, Let-7a-5p/miR-125b-5p (AUC = 0.963), Let-7a-5p/miR-16-5p
(AUC = 0.924) and miR-146a-5p/miR-132-3p (AUC = 0.917), reaching perfect accuracy
when combining any two of them (AUC = 1). Nevertheless, only Let-7a-5p/miR-125b-5p
was significantly higher in patients with microcephaly with respect to patients with normal
head growth (p = 0.035) (Figure 3A).
Finally, RTT patients with vasomotor deficits showed alterations in six miRNA ratios
in plasma, three of them (miR-146a-5p/miR-132-3p, Let-7a-5p/ miR-16-5p and miR-132-3p
/miR-16-5p) with very good biomarker accuracy (Table 5). Combination of Let-7a-5p/miR-
16-5p with either miR-146a-5p/miR-132-3p, miR-132-3p/miR-16-5p or Let-7a-5p/miR-
125b-5p reached maximum efficiency (AUC = 1). The combination of Let-7a-5p/miR-16-
5p with Let-7a-5p/miR-125b-5p or miR-146a-5p/miR-132-3p is the same as that which
identifies patients with microcephaly, while the combination Let-7a-5p/miR-16-5p with
miR-132-3p/miR-16-5p specifically discriminates patients with vasomotor deficits. These
data reflect that all patients with vasomotor deficits also have microcephaly, but not all
patients with microcephaly have vasomotor deficits. Patients with vasomotor deficits
had Let-7a-5p/miR-16-5p significantly higher than controls and patients without deficits
(p = 0.04 and p = 0.029, respectively). Moreover, in patients with vasomotor deficits, miR-
146a-5p/miR-132-3p was higher than in controls (p = 0.042), while miR-24-3p/miR-16-5p
and miR-132-3p/miR-16-5p were higher than in patients without deficits (p = 0.041 and
p = 0.031, respectively) (Figure 3B).
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In summary, we propose that the combination of increased circulating Let-7a-5p/miR-
16-5p and Let-7a-5p/miR-125b-5p or miR-146a-5p/miR-132-3p accurately identifies RTT
patients with microcephaly, while the combination of increased circulating Let-7a-5p/miR-
16-5p and miR-132-3p/miR-16-5p specifically discriminates RTT patients with vasomo-
tor deficits.
3.6. Expression of Potential Biomarkers in RTT Fibroblasts Primary Cultures
To validate that the candidate miRNA biomarkers for RTT identified in plasma (Let-
7a-5p/miR-132-3p, miR-24-3p/miR-132-3p and miR-146a-5p/miR-132-3p) are altered in
RTT patients, we analyzed their expression in an independent cohort of fibroblasts primary
cultures from RTT patients (n = 8), and age and sex matched controls (n = 4). First, we
normalized cellular miRNAs using RNU48, a small-nucleolar RNA commonly used for
microRNA normalization. After normalization, miR-146a-5p was significantly reduced in
RTT fibroblasts (p = 0.008; Table S6) and Let-7a-5p was increased at the limit of significance
(p = 0.075). Next, to avoid normalization bias we performed ratio-based normalization
as with circulating miRNAs in plasma. Ratios of miR-146a-5p/miR-132-3p and miR-24-
3p/miR-132-3p were significantly lower in RTT fibroblasts than in controls (p = 0.003
and p = 0.027, respectively), opposite to the significant increase observed in RTT plasma.
Although not reaching statistical significance, Let-7a-5p/miR-132-3p increased in RTT
fibroblasts (p = 0.086), as in plasma.
Biomedicines 2021, 9, 148 13 of 22
All three ratios showed very good/good biomarker accuracy: miR-146a-5p/miR-
132-3p (AUC = 0.969), Let-7a-5p/miR-132-3p (AUC = 0.844) and miR-24-3p/miR-132-3p
(AUC = 0.844). Taken all together, these data indicate that these three miRNA ratios are
consistently but tissue-specific dysregulated in RTT, and support their biomarker potential
(Table 6, Figure 4).
Table 6. Validation of potential miRNA biomarkers for RTT in fibroblasts primary cultures.
Ratio FC p-Value AUC p-Value 95% CI J Trend n
RTT vs. Controls
miR-146a-5p/miR-132-3p −2.461 0.182 0.004 0.969 0.011 0.876–1 0.875 ↓ 8 vs. 4
miR-24-3p/miR-132-3p −0.719 0.608 0.027 0.844 0.0617 0.612–1 0.625 ↓ 8 vs. 4
Let-7a-5p/miR-132-3p 1.388 2.636 0.086 0.844 0.062 0.617–1 0.75 ↑ 8 vs. 4
FC: Fold Change; AUC: area under the curve; CI: confidence interval; J: Youden index.
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We also analyzed the mRNA expression of LIN28A and THBS3 in fibroblasts, and we
found no differences between RTT and controls (Table S6). The lack of differences between
conditions might be due to the reduced number of samples (4 RTT and 4 controls) or to
tissue-specific regulation in blood and fibroblasts.
4. Discussion
The search for quantitative biomarkers is instrumental in complex heterogenic rare
diseases, like RTT or MDS, especially those biomarkers that could be informative at early
stages or used to monitor disease progression and the effect of treatments in clinical trials,
as clinical severity scores are not optimal outcome measures [32,47,48]. In particular, the
identification of reliable biomarkers for RTT early screening can contribute to a prompt
genetic diagnostic, as the main age at RTT diagnosis is 24 months due to the apparently
normal development that precedes the onset of overt symptoms [49].
RNA blood-based biomarkers are easy to measure repeatedly from patients of all
ages and health conditions [50,51] although there are several challenges. The first one
is the lack of direct connection between blood and brain, especially in diseases without
brain–blood–barrier disruption, like RTT-related syndromes [52]. As the use of nervous
tissue is highly restricted in living patients, other biological fluids (cerebrospinal fluid,
saliva or urine) and skin fibroblasts could help to validate the relevance of the potential
RNA biomarkers. Nevertheless, one must consider that a particular biomarker could be
differentially dysregulated in distinct tissues.
Changes in mRNA expression do not always reflect similar changes in protein function,
although they can be indicative of a misbalanced situation. miRNAs post-transcriptionally
regulate mRNAs by binding to partially complementary sites, causing translational sup-
pression and/or degradation [53]. Moreover, a single miRNA can regulate the expression
of an entire set of proteins. Despite the lack of standardized internal controls, miRNAs are
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attractive biomarker candidates, as they can reflect the pathogenic state of the system and
are highly stable [33,34]. Circulating microRNAs are involved in neural development and
plasticity [54,55], and are altered in neuropsychiatric disorders like schizophrenia, autism
spectrum disorders [35,36] or recently in RTT [47].
In addition to the above-described limitations, the main drawback of this exploratory
study is inherent to the reduced sample size, as RTT and MDS are rare disorders. Moreover,
the strict exclusion criteria applied to ensure the robustness of the results forced the rejection
of plasma samples with hemolysis, which further reduced the sample size in the miRNA
study. Hemolysis was higher in samples from controls <15 years, preventing statistical
analysis using this age group.
Previous studies have described nonlinear changes from infancy to adulthood in some
of the studied RNAs. For example, miR-483-5p expression in mononuclear leucocytes
was constant from infancy to childhood, decreasing thereafter during adulthood. On the
contrary, miR-24 and Let-7a increased from children to young adults, decreasing thereafter
during ageing [56]. In our study, we only found a statistical correlation with age in the miR-
483-5p/miR-16-5p ratio and in MECP2 E2, agreeing with previously published results [38].
Nevertheless, due to the reduced sample size, we cannot rule out additional changes
associated with age in other RNAs.
Due to the lack of reference controls, studies of miRNAs required additional method-
ological considerations. We found that the levels of miR-16-5p, Let-7a-5p, miR-24-3p,
miR-146a-5p and miR-125b-5p in a fixed plasma volume were significantly higher in RTT
samples than in controls. These data sustain impaired protein translation in RTT, and
agree with recent studies in the cerebellum of pre-symptomatic Mecp2-/y mice showing
increased levels of miR-125b-5p, Let-7a-5p, miR-146a-5p and miR-24-3p and reduced levels
of LIN28A [36,57]. As described in the methods section, we calculated miRNA ratios to
avoid normalization bias.
Even with all these limitations, here we have identified a set of circulating miRNA
in plasma, candidates for biomarker panels with clinical potential for RTT screening and
stratification (Table 7). We also provided a preliminary validation of three miRNA pairs, as
RTT biomarkers using an independent cohort of skin fibroblasts. Two of the three miRNA
ratios (miR-146a-5p/miR-132-3p and miR-24-3p/miR-132-3p) were dysregulated in both
tissues, but in opposite directions. This phenomenon has been previously described in other
studies [58,59], and may be due to different expression between circulating and cellular
miRNAs [60] or due to the distinct role of these miRNAs in different tissues. Nevertheless,
their clinical relevance will require further verification and validation in studies with larger
cohorts including samples of a whole range of ages.
Table 7. Summary of potential circulating miRNA biomarkers for RTT screening and stratification.
Trend
RTT
miR-24-3p/miR-132-3p + miR-146a-5p/miR-132-3p ↑
Microcephaly
Let-7a-5p/miR-125b-5p + Let-7a-5p/miR-16-5p ↑
Let-7a-5p/ miR-16-5p + miR-146a-5p/miR-132-3p ↑
Let-7a-5p/miR-125b-5p + miR-146a-5p/miR-132-3p ↑
Vasomotor deficits
Let-7a-5p/miR-16-5p + miR-132-3p/miR-16-5p ↑
The differentially expressed RNAs identified in this work in blood, plasma and
fibroblasts from RTT patients are mainly involved in growth, metabolism, extracellular
matrix and inflammation. Figure 5 summarizes the main signaling pathways involved.
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ciated with Let-7f-mediated reduction of Insulin-Like Growth Factor 1 (IGF1) protein syn-
thesis [57]. IGF1 is the indicated treatment for growth failure and, based on data obtained 
from male Mecp2-/y mice, several phase II clinical trials of IGF1 analogs are being tested 
for RTT. These studies have reported improvements in cognition and social abilities, alt-
hough chronic treatment could have detrimental effects, like metabolic syndrome and ep-
ilepsy, depending on the dosage [84–87]. 
Nevertheless, the low LIN28A and miR-483-5p/miR-16-5p ratio expression in young 
RTT patients suggests an early blockage of IGF2 signaling at different regulatory points. 
Thus, miR-483-5p/miR-16-5p is a potential candidate biomarker for an early screening 
panel of diseases associated with growth delay, including RTT. Moreover, within RTT 
patients, higher Let-7a-5p/miR-125b-5p and Let-7a-5p/miR-16-5p ratios combination seg-
regates those with microcephaly, a prominent feature in the disease [88,89]. To determine 
if this early dysregulation is specific for RTT or is a general trait for growth restriction, 
further studies should compare cohorts of young RTT patients with cohorts of children 
coursing with growth restriction, developmental delay and age and sex-matched controls. 
Moreover, opposed to what was observed in our RTT cohort, reduced Let-7a-5p and 
increased miR-483-5p were described in peripheral blood of a cohort of Chinese patients 
with autism spectrum disorders (ASD) [90], pointing to similar signaling pathways mis-
balanced into opposite directions.  
i r . i r f t r s ri ci l si li t s i l i . ti s li f r ir ct ff ct
i li .
BDNF is a member of the neurotrophin family expressed in an activity-dependent
manner and involved in the control of neuronal survival, development, synaptic function
and plasticity [61–64]. BDNF is the most extensively studied target of MeCP2 and its
expression is highly dysregulated in RTT [65]. The link between MeCP2 and BDNF is
complex and may involve a set of common signaling pathways. Although in this study
BDNF protein dosage was not significantly altered in RTT patients, we report alterations
in various MeCP2 and BDNF effectors including LIN28A [40] and several miRNAs (i.e.,
miR-24, miR-125b, miR-132 [66] and miR-16 [67]) that may underlie some of the pathogenic
symptoms in RTT syndrome.
The LIN28/Let-7 loop is a primal regulator of glucose metabolism, proliferation,
growth, stem cells differentiation, inflammation and miRNA-selective translation [40,68–70].
LIN28A/B are RNA-binding proteins that post-transcriptionally regulate developmental
genes and block the processing of Let-7 family of microRNAs, facilitating their degra-
dation [71–73]. Let-7 miRNAs inhibit translation of an important subset of pro-growth
proteins and accordingly, Let-7 expression during embryonic development is virtually
absent, increasing over development up to the 50% of miRNAs in mature neurons [74–77].
At the same time, LIN28A expression is repressed by Let-7, creating a loop of regula-
tion [78]. We showed here a dysregulation in this loop, with reduced LIN28A and increased
Let-7a expression.
LIN28A also regulates Insulin-like growth factor 2 (IGF2)-mTOR signaling, controlling
neural progenitor proliferation and brain development [79]. LIN28A induces IGF2 expres-
sion [80] while Let-7a-5p, miR-125b-5p and miR-16-5p downregulate IGF2 by targeting
several components of IGF2 signaling [68,81,82]. IGF2 is a developmentally regulated and
maternally imprinted gene that contains embedded within it the miR-483-5p [38]. The
miR-483-5p itself upregulates IGF2 transcription from fetal promoters and enhances tissue
growth [83]. Specifically in humans, miR-483-5p regulates the translation of MeCP2 [38].
Recently, reduced levels of LIN28A in the cerebellum of Mecp2-/y are associated with
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Let-7f-mediated reduction of Insulin-Like Growth Factor 1 (IGF1) protein synthesis [57].
IGF1 is the indicated treatment for growth failure and, based on data obtained from male
Mecp2-/y mice, several phase II clinical trials of IGF1 analogs are being tested for RTT.
These studies have reported improvements in cognition and social abilities, although
chronic treatment could have detrimental effects, like metabolic syndrome and epilepsy,
depending on the dosage [84–87].
Nevertheless, the low LIN28A and miR-483-5p/miR-16-5p ratio expression in young
RTT patients suggests an early blockage of IGF2 signaling at different regulatory points.
Thus, miR-483-5p/miR-16-5p is a potential candidate biomarker for an early screening
panel of diseases associated with growth delay, including RTT. Moreover, within RTT
patients, higher Let-7a-5p/miR-125b-5p and Let-7a-5p/miR-16-5p ratios combination
segregates those with microcephaly, a prominent feature in the disease [88,89]. To determine
if this early dysregulation is specific for RTT or is a general trait for growth restriction,
further studies should compare cohorts of young RTT patients with cohorts of children
coursing with growth restriction, developmental delay and age and sex-matched controls.
Moreover, opposed to what was observed in our RTT cohort, reduced Let-7a-5p
and increased miR-483-5p were described in peripheral blood of a cohort of Chinese
patients with autism spectrum disorders (ASD) [90], pointing to similar signaling pathways
misbalanced into opposite directions.
Aside from growth and glucose metabolism, most genes and miRNAs altered in this
study point toward inflammation as a process implicated in RTT pathogenesis [91,92].
NF-κB signaling is upregulated in MeCP2-/y mice and its inhibition ameliorated RTT
phenotype; thus, this pathway is postulated as a very promising drug target [30,93]. IRAK1
is a signaling kinase of the NF-κB pathway, also upregulated in MeCP2-/y mice. IRAK1
gene is adjacent to MECP2 and both are duplicated in all patients affected by MDS [6,94].
In whole blood, IRAK1 expression showed age-dependent changes in RTT, from lower in
young patients than in controls, to higher in older patients than in controls. Moreover,
miR-146a-5p was upregulated. miR-146a-5p is a key piece of a negative regulatory loop
of NF-κB pathway, as its expression is induced by NF-κB and downregulates both IRAK1
and TRAF6, two adapter molecules of this pathway [95]. Another regulatory mechanism
involves miR-24-3p inhibition of IRAK-M expression [96]. IRAK-M suppresses IRAK1/4
signaling and negatively regulates inflammation and immune response in macrophages
and monocytes [97–99]. In addition, recent works implicate miR-16-5p, miR-24-3p and
miR-146a-5p in the regulation of MAPK downstream BDNF, IGF2 and WNT signaling in
depression [100].
THBS1-5 genes codify for thrombospondins (TSP1-5), a family of extracellular matrix
proteins with a whole range of tissue-specific functions depending on their interaction
with different membrane receptors [101]. TSP-1 expression is downregulated in several
diseases associated with mental retardation, such as Down syndrome [102] or Fragile X
syndrome [103]. Restoration of TSP-1 levels in glia modulated spine number and morphol-
ogy; thus, TSP-1 is postulated as a target for the treatment of these conditions. Defects
in spine density, morphology and dendritic arborization are also present in post-mortem
RTT brains and mice models [104–106]. Although in THBS1 mRNA did not change sig-
nificantly in our study, we cannot exclude altered THBS1 protein translation as it is a
target of Let-7a-5p [82,107], and Let-7a-5p/miR-132-3p ratio is elevated in RTT patients.
TSP-3 functions in the brain are largely unknown; nevertheless, we have recently found a
positive correlation between high THBS3 mRNA in blood and deficits in executive function,
attention, behavioral and mood disorders in patients with inborn errors of amino acid
metabolism [108]. As TSPs are highly expressed in glial cells, our data support the current
view that glial cells can be central in RTT phenotype, and thus, can be targets for potential
treatments [109].
Finally, vasomotor deficits are also prevalent in RTT patients as they grow old. Al-
tered miR-146a-5p/miR-132-3p and Let-7a-5p/miR-16-5p are the most relevant ratios to
identify patients with vasomotor deficits from those without these deficits and controls.
Biomedicines 2021, 9, 148 17 of 22
Concordantly, alterations in all these miRNAs have been described in angiogenesis-related
diseases [110–112]. Our data point to increased circulating miR-146a-5p/miR-132-3p ratio
as a hallmark of RTT that can identify patients from controls with very good accuracy,
while it also serves to stratify RTT severity, being able to discriminate those patients with
microcephaly or vasomotor deficits. On the contrary, increased Let-7a-5p/miR-16-5p and
miR-132-3p/miR-16-5p ratios combination specifically identifies vasomotor deficits, and thus,
it could be included in a panel for detection of vasomotor deficits in non-RTT pathologies.
5. Conclusions
Our exploratory study identifies potential miRNA biomarkers with clinical relevance,
and sets the basis for larger studies leading to the identification of specific miRNA signa-
tures suitable for early RTT screening and/or as quantitative outcome measures in clinical
trials. We also described several dysregulated miRNA pairs appropriate for tracking dis-
ease progression. Those miRNA pairs are key for differentiation, growth and inflammation,
some of the prominent features of RTT, and could serve as targets for potential treatments.
However, their clinical relevance will require further verification and validation in studies
with larger cohorts including samples of a whole range of ages.
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